[go: up one dir, main page]

CN107108747A - 具有共同轻链的双特异性抗体或抗体混合物 - Google Patents

具有共同轻链的双特异性抗体或抗体混合物 Download PDF

Info

Publication number
CN107108747A
CN107108747A CN201680005167.4A CN201680005167A CN107108747A CN 107108747 A CN107108747 A CN 107108747A CN 201680005167 A CN201680005167 A CN 201680005167A CN 107108747 A CN107108747 A CN 107108747A
Authority
CN
China
Prior art keywords
antigen
antibody
light chain
binding portion
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680005167.4A
Other languages
English (en)
Other versions
CN107108747B (zh
Inventor
徐霆
须涛
汪皛皛
李倩
逄敏洁
张慧敏
韩莉
张庆青
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Alphamab Co Ltd
Original Assignee
Suzhou Alphamab Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Alphamab Co Ltd filed Critical Suzhou Alphamab Co Ltd
Priority to CN202111616341.8A priority Critical patent/CN114276458A/zh
Publication of CN107108747A publication Critical patent/CN107108747A/zh
Application granted granted Critical
Publication of CN107108747B publication Critical patent/CN107108747B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了具有共同轻链的双特异性抗体或抗体混合物及其制备方法。本发明还提供了编码所述抗体或混合物的核酸分子、含有该核酸分子的重组载体和重组细胞，以及所述抗体或混合物的检测和定量方法。

Description

PCT国内申请，说明书已公开。

Claims (45)

  1. PCT国内申请，权利要求书已公开。
CN201680005167.4A 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物 Active CN107108747B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111616341.8A CN114276458A (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510008045.8A CN105820251B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN2015100080458 2015-01-08
PCT/CN2016/070447 WO2016110267A1 (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111616341.8A Division CN114276458A (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物

Publications (2)

Publication Number Publication Date
CN107108747A true CN107108747A (zh) 2017-08-29
CN107108747B CN107108747B (zh) 2022-02-08

Family

ID=56355539

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201910869921.4A Active CN110658340B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN201910857990.3A Active CN110655582B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN201510008045.8A Active CN105820251B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN201680005167.4A Active CN107108747B (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN202111616341.8A Pending CN114276458A (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CN201910869921.4A Active CN110658340B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN201910857990.3A Active CN110655582B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物
CN201510008045.8A Active CN105820251B (zh) 2015-01-08 2015-01-08 具有共同轻链的双特异性抗体或抗体混合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111616341.8A Pending CN114276458A (zh) 2015-01-08 2016-01-08 具有共同轻链的双特异性抗体或抗体混合物

Country Status (7)

Country Link
US (2) US10808043B2 (zh)
EP (1) EP3243840B8 (zh)
JP (1) JP7041516B2 (zh)
CN (5) CN110658340B (zh)
DK (1) DK3243840T3 (zh)
ES (1) ES2811267T3 (zh)
WO (1) WO2016110267A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799546A (zh) * 2017-09-01 2020-02-14 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
WO2022179507A1 (en) * 2021-02-23 2022-09-01 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Methods of preventing, alleviating or treating tumors

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6510532B2 (ja) 2013-12-20 2019-05-08 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｈｅｒ２抗体及び使用方法
CN107446045A (zh) * 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 一种抗her2的抗体、其药物组合物及用途
CN106248971B (zh) * 2016-08-19 2017-10-03 合肥瀚科迈博生物技术有限公司 用于检测人血清中her2含量的elisa试剂盒、使用方法及用途
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES WITH COMMON LIGHT CHAIN AND METHOD OF USE
CN107064092B (zh) * 2017-05-08 2019-12-13 上海药明生物技术有限公司 一种双特异性抗体生物学活性与滴度检测方法及其应用
US12049517B2 (en) 2017-08-01 2024-07-30 Ab Studio Inc. Bispecific antibodies and uses thereof
CN111518213B (zh) * 2019-02-03 2024-05-28 上海宝济药业股份有限公司 抗her2的双特异性抗体及其应用
US11254736B2 (en) * 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
MX2021012003A (es) * 2019-04-02 2021-11-04 Kenjockety Biotechnology Inc Anticuerpos multiespecificos contra antigeno de cancer de la bomba de eflujo y composiciones, reactivos, kits y metodos relacionados con los mismos.
US20230017515A1 (en) * 2019-12-04 2023-01-19 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. COMBINATION OF BISPECIFIC FUSION PROTEIN AND ANTI-Her2 ANTIBODY FOR TUMOR TREATMENT
EP4097134A1 (en) * 2020-01-29 2022-12-07 Kenjockety Biotechnology, Inc. Anti-mdr1 antibodies and uses thereof
CN114245753A (zh) * 2020-03-27 2022-03-25 江苏康宁杰瑞生物制药有限公司 用于肿瘤治疗的抗her2抗体与cdk抑制剂的组合
EP4126968A4 (en) * 2020-03-27 2024-03-27 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Efficacious dose for her2 bispecific antibody
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN116096758A (zh) * 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
WO2021226984A1 (zh) 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
CN113754774A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗pd-l1和egfr的四价双特异性抗体
JP2023551113A (ja) * 2020-11-06 2023-12-07 バイオ－テラ ソリュ－ションズ，エルティーディー． 二重特異性抗体及びその応用
EP4253415A4 (en) * 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor
CN114539413A (zh) * 2020-11-25 2022-05-27 三生国健药业（上海）股份有限公司 结合her2的多价双特异性抗体、其制备方法和用途
US20240307551A1 (en) * 2021-07-05 2024-09-19 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Antibody-drug conjugate and application thereof
KR20250022761A (ko) 2022-06-10 2025-02-17 후지필름 다이오신쓰 바이오테크놀로지스 유케 리미티드 세포의 작출 방법, 헤테로 다량체 단백질의 제조 방법, 바이스페시픽 항체의 제조 방법, 벡터 세트, 포유동물 세포, cho 세포, 및 세포 풀의 작출 방법
WO2024230772A1 (zh) * 2023-05-09 2024-11-14 江苏康宁杰瑞生物制药有限公司 包含抗her2双特异性抗体的联合治疗药物及其用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299370A (zh) * 1998-05-06 2001-06-13 基因技术股份有限公司 用离子交换层析纯化蛋白质
CN1668636A (zh) * 2002-07-18 2005-09-14 克鲁塞尔荷兰公司 抗体混合物的重组生产
CN102558355A (zh) * 2011-12-31 2012-07-11 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
JP2012515540A (ja) * 2009-01-26 2012-07-12 ゲンマブ エー／エス 抗体混合物を産生するための方法
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
CN103388013A (zh) * 2012-07-25 2013-11-13 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
US6485943B2 (en) * 1995-01-17 2002-11-26 The University Of Chicago Method for altering antibody light chain interactions
US6410690B1 (en) * 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
SG170110A1 (en) * 2006-03-10 2011-04-29 Macrogenics Inc Identification and engineering of antibodies with variant heavy chains and methods of using same
US8652466B2 (en) * 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
PT2235064E (pt) * 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CN103261220B (zh) * 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
SG10201913376XA (en) * 2012-04-20 2020-02-27 Merus Nv Methods and means for the production of ig-like molecules
US9562110B2 (en) * 2012-11-21 2017-02-07 Wuhan Yzy Biopharma Co., Ltd. Bispecific antibody
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN107789631B (zh) * 2017-11-03 2021-03-16 合肥瀚科迈博生物技术有限公司 抗人ErbB2双表位抗体-药物偶联物及其应用
CN111518213B (zh) * 2019-02-03 2024-05-28 上海宝济药业股份有限公司 抗her2的双特异性抗体及其应用
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
EP4253415A4 (en) * 2020-11-12 2024-10-02 Mabwell (Shanghai) Bioscience Co., Ltd. Antibody and preparation method therefor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299370A (zh) * 1998-05-06 2001-06-13 基因技术股份有限公司 用离子交换层析纯化蛋白质
CN1668636A (zh) * 2002-07-18 2005-09-14 克鲁塞尔荷兰公司 抗体混合物的重组生产
JP2006515503A (ja) * 2002-07-18 2006-06-01 クルセル ホランド ベー ヴェー 抗体混合物の組換え生産
JP2012515540A (ja) * 2009-01-26 2012-07-12 ゲンマブ エー／エス 抗体混合物を産生するための方法
WO2012143523A1 (en) * 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
CN102558355A (zh) * 2011-12-31 2012-07-11 苏州康宁杰瑞生物科技有限公司 基于电荷网络的异二聚体fc改造方法及异二聚体蛋白的制备方法
CN103388013A (zh) * 2012-07-25 2013-11-13 苏州康宁杰瑞生物科技有限公司 利用电荷排斥作用制备同二聚体蛋白混合物的方法
CN105829347A (zh) * 2013-12-20 2016-08-03 豪夫迈·罗氏有限公司 双特异性her2抗体及使用方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
A M MERCHANT 等: "An efficient route to human bispecific IgG", 《NAT BIOTECHNOL》 *
BOHUA LI 等: "Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization", 《CANCER RES》 *
GENBANK: "Chain A, Herceptin Fab (antibody) - Light Chain", 《GENBANK》 *
JANET JACKMAN 等: "Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling", 《J BIOL CHEM》 *
MATTHEW C FRANKLIN 等: "Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex", 《CANCER CELL》 *
任辉 等: "基因工程HER2/CD3双特异抗体抑制乳腺癌生长的实验研究", 《中华普通外科杂志》 *
林贵高: "丙型肝炎患者血清抗NS3/NS5天然双特异性抗体的鉴定及其产生机制的研究", 《中国博士学位论文全文数据库医药卫生科技辑》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799546A (zh) * 2017-09-01 2020-02-14 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
CN110799546B (zh) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
WO2022179507A1 (en) * 2021-02-23 2022-09-01 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Methods of preventing, alleviating or treating tumors

Also Published As

Publication number Publication date
CN110655582B (zh) 2022-12-16
ES2811267T3 (es) 2021-03-11
EP3243840A1 (en) 2017-11-15
CN110658340A (zh) 2020-01-07
US10808043B2 (en) 2020-10-20
CN110658340B (zh) 2023-10-31
US11396557B2 (en) 2022-07-26
US20190031782A1 (en) 2019-01-31
CN110655582A (zh) 2020-01-07
EP3243840A4 (en) 2018-09-12
EP3243840B1 (en) 2020-07-15
CN105820251A (zh) 2016-08-03
CN105820251B (zh) 2019-10-15
JP7041516B2 (ja) 2022-03-24
EP3243840B8 (en) 2020-08-26
DK3243840T3 (da) 2020-08-24
JP2018504113A (ja) 2018-02-15
US20210070885A1 (en) 2021-03-11
CN107108747B (zh) 2022-02-08
WO2016110267A1 (zh) 2016-07-14
CN114276458A (zh) 2022-04-05

Similar Documents

Publication Publication Date Title
US11396557B2 (en) Bispecific antibody or antibody mixture with common light chains
CN113015749B (zh) 靶向cd3的抗体、双特异性抗体及其用途
TWI845767B (zh) 抗人Claudin18.2抗體及其應用
WO2020098599A1 (zh) 抗cd73抗体、其抗原结合片段及应用
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
TWI843799B (zh) 抗pd-1抗體、其抗原結合片段及醫藥用途
CN104520317A (zh) 针对高度保守靶标的包含来自骆驼科之序列的抗体
JP2021510078A (ja) Ｐｄ−ｌ１抗体、その抗原結合フラグメント、及びその製薬学的使用
CN112243443B (zh) 抗trop-2抗体、其抗原结合片段及其医药用途
WO2023151693A1 (zh) 包含抗tigit抗体和抗pd-1-抗vegfa双特异性抗体的药物组合物及用途
JP2020508658A (ja) Ｔｉｍ−３抗体、その抗原結合断片、及びそれらの医学的使用
WO2024032777A1 (zh) 抗cd73抗体或其抗原片段及其应用
TW202128765A (zh) 一種雙特異性抗體
CN114276451A (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
EP4454706A1 (en) Novel egfr binding proteins
CN116744971A (zh) 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
CN116234573A (zh) 抗trop-2抗体、其抗原结合片段或其突变体、及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1242350

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20180906

Address after: 215125 G-310 388 Suzhou, Jiangsu Industrial Park, Suzhou

Applicant after: SUZHOU ALPHAMAB Co.,Ltd.

Address before: 215125 C23, biological park, No. 218, Xing Hu Street, Suzhou Industrial Park, Suzhou, Jiangsu.

Applicant before: SUZHOU ALPHAMAB Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment
EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20170829

Assignee: SHANGHAI JMT-BIO TECHNOLOGY Co.,Ltd.

Assignor: SUZHOU ALPHAMAB Co.,Ltd.

Contract record no.: X2024990000668

Denomination of invention: Bispecific antibodies or antibody mixtures with a common light chain

Granted publication date: 20220208

License type: Exclusive License

Record date: 20241217